Vanguard Asset Management
IMVT icon

Vanguard Asset Management’s Immunovant IMVT Stock Holding History

Vanguard Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Sell
64,791
-4,651
-7% -$142K ﹤0.01% 1449
2026
Q1 		$1.72M Buy
+69,442
New +$1.8M ﹤0.01% 1531

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Asset Management's IMVT Position: Q2 2026 in Review

Vanguard Asset Management reduced its Immunovant (IMVT) stake by 6.7% in Q2 2026, selling an estimated $142K and leaving 64,791 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1449.

Vanguard Asset Management first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Vanguard Asset Management held 64,791 shares of Immunovant worth $2.5M as of Q2 2026.
  • Vanguard Asset Management sold 4,651 Immunovant shares in Q2 2026, an estimated $142K.
  • Immunovant made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1449 holding.
  • Vanguard Asset Management first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
  • 223 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.